Health Condition 1: null- All patients were either Bed ridden and on ventilator support system.
Conditions
Interventions
Intervention1: THERAPEUTIC PLASMA EXCHANGE: first line treatment for patients of Guillain Barre Syndrome
Control Intervention1: INTRAVENOUS IMMUNOGLOBULIN: first line treatment for patients of Guillai
Sponsors
Department of Transfusion Medicine PGIMER
Eligibility
Inclusion criteria
Inclusion criteria: GBS patient chosen for the study purpose within four weeks of onset of weakness following Ausbury criteria and ranging from 13 to 60 years of age.
Exclusion criteria
Exclusion criteria: 1. Duration of illness more than 30 days before entry in study. 2. Children less than or equal to 12 year of age. 3. Any contraindication for IVIG or TPE. 4. Patient with hypokalemia and porphyria. 5. Specific exclusions with atypical features such as-- a.Purely sensory symptoms. b.Cranial nerve palsies without significant limb weakness. c.Previous acute polyneuropathy. d.Improvement of one or more disability grades before inclusion e.Pregnancy. f. Previous therapy with immunosuppressive drugs other than steroids. g. Previous plasmapheresis / IVIG therapy. h. Patient not willing to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incremental cost per unit recovery in grade of Guillain Barre syndrome disability scoreTimepoint: Time horizon for the study was 12 weeks during which all major effects and costs were assessed and outcome at 12 weeks were measured. | — |
Secondary
| Measure | Time frame |
|---|---|
| comparing other tools( MRC SUM SCORE AND ONLS SCORE) for assessment for functional improvement in GBSTimepoint: Time horizon for the study was 12 weeks during which all major effects and costs were assessed and outcome at 12 weeks were measured. | — |
Countries
India
Contacts
Public ContactAshish Maheshwari
PGIMER
Outcome results
None listed